This article was originally published in The Gray Sheet
Executive SummaryNon-invasive fat reduction system will be available in the U.S. immediately after receiving 510(k) clearance, announced Sept. 8. Zeltiq received a CE mark in September 2009 for the controlled cooling technology (1"The Gray Sheet" June 7, 2010). The non-surgical substitute for liposuction is based on the natural biologic susceptibility of fat cells to cold. The CoolSculpting system kills underlying fat cells and does not affect the skin tissue, the firm explains
You may also be interested in...
The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.